September 7, 2018 Acad, Gov/Utilities Lab Top-10 PR/Corporate

Agilent Early Career Professor Award Presented to Christoph Thaiss at University of Pennsylvania

Agilent Early Career Professor Award Presented to Christoph Thaiss at University of Pennsylvania Penn microbiologist recognized for groundbreaking microbiome research SANTA CLARA, Calif., September 7, 2018 Agilent Technologies Inc. (NYSE: A) today announced that the winner of the 2018 Agilent Early Career Professor Award is Christoph Thaiss, Ph.D., assistant professor of microbiology in the Perelman... Read more

August 27, 2018 Acad, Gov/Utilities Licensing, IP, and Legal PR/Corporate

Xylem Inc. to participate at the Seaport Global Energy & Industrials Conference

RYE BROOK, N.Y.–(BUSINESS WIRE)–Aug. 27, 2018– Xylem Inc. (NYSE:XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its Senior Vice President and President, Americas Commercial Team and Applied Water SystemsKen Napolitano and Sr. Director of Investor Relations Matt Latino will participate in the Seaport Global... Read more

August 21, 2018 Acad, Gov/Utilities Clinical Research/Diagn. Lab Top-10

Agilent Companion Diagnostic Gains Expanded FDA Approval in Urothelial Carcinoma

Agilent Companion Diagnostic Gains Expanded FDA Approval in Urothelial Carcinoma PD-L1 IHC 22C3 pharmDx Now Approved to Identify Certain Urothelial Carcinoma Patients for Treatment With KEYTRUDA(R) (pembrolizumab) SANTA CLARA, Calif., August 21, 2018 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3... Read more

August 13, 2018 Acad, Gov/Utilities

FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies

Basel, 13 August 2018 FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies There are currently no FDA-approved treatments that help prevent severe reactions due to food allergies As many as 15 million Americans have food allergies – including approximately 6 million children – and the incidence is increasing Roche (SIX: RO, ROG;... Read more

August 3, 2018 Acad, Gov/Utilities

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease

Basel, 03 August 2018 PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting... Read more

August 3, 2018 Acad, Gov/Utilities

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease

Basel, 03 August 2018 PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting... Read more